Trial Search Results

Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers

The purpose of the study is to determine whether standardized implementation of a scripted template for discussing important issues that arise near the end of life improves the care of those who have advanced cancer.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):

Intervention(s):

  • Behavioral: Serious Illness Conversation Guide (SICG)
  • Behavioral: Quality of Life (QOL) survey

Phase:

N/A

Eligibility


Inclusion Criteria:

   - Patients with metastatic colorectal cancer whose tumor has progressed on both FOLFOX
   and FOLFIRI.

   - Exception: Patients with metastatic colorectal cancer whose tumors demonstrate a BRAF
   V600E mutation may be enrolled regardless of prior chemotherapy.

   - Exception: Patients whose tumors are MSI-H must have experience progression through
   immunotherapy in addition to the therapies mentioned above.

   - Patients with metastatic pancreatic adenocarcinoma.

   - Patients with metastatic gastric or esophageal cancer whose tumor has progressed
   through first-line chemotherapy of any type.

   - Patients with metastatic cholangiocarcinoma whose tumor has progressed through
   first-line chemotherapy of any type.

   - Patients with metastatic hepatocellular carcinoma whose tumor has progressed through
   PD1 blockade.

   - Patients with metastatic high-grade neuroendocrine tumor.

   - A patient with a metastatic GIST that has progressed through first-line tyrosine
   kinase inhibitor.

   - Expected life expectancy of at least one month

Exclusion Criteria:

   - Any patient not meeting the above criteria

   - Non-English speaking patients

Ages Eligible for Study

N/A - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Daniel Holguin
6507363379
Recruiting